To further activate purinergic receptors, before infection, we pre-treated for 5 min with BzATP (Benzoylbenzoyl-ATP, 2′(3′)-O-(4-Benzoylbenzoyl) adenosine 5′-triphosphate, 300 μM), a P2X7 non-hydrolyzable agonist, which resulted in higher HIV entry, 11.9±0.9, compared to HIV alone at all the time points examined (Figure 4C, BzATP, n=4, *p≤0.005 compared to control conditions, and #p≤0.005 compared to HIV condition). The gene discussed is P2RX1; the disease is infection.